All peptides
Cagrilintide
Research / Investigational
Cagrilintide is a long-acting amylin receptor agonist under investigation for chronic weight management, most notably as the CagriSema combination.
Buy Cagrilintide on American Peptides
Affiliate link — we may earn a commission at no extra cost to you.
Overview
Cagrilintide is a long-acting amylin receptor agonist under investigation for chronic weight management, most notably as the CagriSema combination.
FDA Approval Status
Not approved by the FDA. Investigational or intended for research purposes only.
Mechanism of Action
Activates amylin and calcitonin receptors to slow gastric emptying and promote satiety.
Current Research
Phase II trials show meaningful weight loss alone and additive effects with semaglutide.
Research strength: Moderate
Potential Medical Uses
- Investigational only
Potential Benefits
- Appetite suppression
- Synergy with GLP-1 agonists
Known Side Effects
- Nausea
- Injection-site reactions
Contraindications
- Hypersensitivity
- Pregnancy
Drug Interactions
- Insulin (hypoglycemia)
- GLP-1 agonists (additive GI effects)
Administration Methods
- Subcutaneous injection weekly
Half-life
~7 days
Reconstitution
Prefilled trial device.
Storage & Handling
Refrigerated.
References & Sources
Frequently Asked Questions
Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.